T-DM1 is approved and reimbursed for residual disease after neoadjuvant treatment with trastuzumab, whereas the double blockade with pertuzumab and trastuzumab is approved and reimbursed in the adjuvant setting in Italy only for high-risk HER2+ BC patients (6, 7). This evidence concerns the gene ERBB2 and breast cancer.